Amol Akhade/LinkedIn
Mar 30, 2025, 12:14
Amol Akhade: Will Laura trial show OS benifit at 60 % maturity?
Amol Akhade, Senior consultant medical oncologist and hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals, reshared his post on X, adding:
“Will Laura show OS benifit at 60 % maturity?
This is what AI thinks. Can any AI expert use current data and predict OS for Laura at 60 % maturity of data (current is 31 % mature).”
Quoting Amol Akhade‘s original post:
“Updated OS curves of Laura trial. Data yet to fully mature. 80 % Cross over. Do u think it will show os eventually?”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 1, 2025, 12:16
Apr 1, 2025, 12:13
Apr 1, 2025, 12:07
Apr 1, 2025, 11:53
Apr 1, 2025, 11:51
Apr 1, 2025, 11:42